BLSMBlossomHill TherapeuticsSigning up patients
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NSCLC (Advanced Non-small Cell Lung Cancer)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 675 (planned)
- Started
- Jan 9, 2025
- Main results expected
- Jan 31, 2029
- Fully finished
- Jul 31, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation)
Measured over: Within the first 21 days of the first dose of BH-30643.
Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization)
Measured over: Within 21 days of last participant dosed during Dose Expansion/Optimization.
Objective Response Rate (ORR) (Phase 2)
Measured over: Approximately 3 years after the first participant dosed.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06706076 · record last updated 2026-11-04 · checked 2026-11-09 15:36 UTC